
One of the most common questions researchers and clinics ask before ordering any peptide is a version of "is this legal to have?" The honest answer starts with recognising that not every regulated substance sits in the same bucket. Broadly speaking, compounds handled in the UAE fall into categories with quite different rules: licensed prescription medicines that have gone through formal drug-registration and are marketed under an approved brand for human therapeutic use; controlled or scheduled substances covered by narcotics and psychotropic legislation; and unscheduled research chemicals — materials supplied for laboratory, analytical, or research purposes, explicitly labelled as not for human consumption.
Retatrutide, as supplied by REVIVE LAB UAE, sits in the third category. It is not a narcotic, it is not currently scheduled as a controlled substance, and it is not marketed anywhere as an approved prescription drug under a specific brand name. That places it in a materially different regulatory position than, say, insulin or a registered weight-management pharmaceutical — even though the underlying research area (metabolic and incretin biology) overlaps.
Retatrutide is a synthetic peptide research compound studied as a triple agonist acting on GLP-1, GIP and glucagon receptor pathways. It remains an investigational molecule in the broader pharmaceutical research world — meaning that, to REVIVE's knowledge, it has not completed the registration and approval process that would let any company market it as a licensed prescription medicine under a specific brand name in the UAE or elsewhere. Because it isn't an approved pharmaceutical product and isn't scheduled as a controlled substance, research-grade Retatrutide supplied with clear non-human-consumption labelling generally falls into the unscheduled research-chemical category described above.
This is a general, high-level description of how the category works — not a specific legal ruling. Regulatory classifications can be interpreted differently depending on context, and REVIVE LAB UAE is not a law firm. If your work requires certainty on how a specific shipment, institution, or use case will be treated, that determination should come from UAE customs authorities, MOHAP, or a qualified lawyer familiar with your circumstances.
A separate question from "is the compound scheduled" is "how does it move across the border." Anyone importing any material into the UAE personally — whether a peptide, a supplement, or an unrelated chemical — is generally responsible for understanding what documentation, declarations, and permits their shipment may require, and for how customs authorities classify that specific parcel on arrival. Personal international shipments can be delayed, queried, or held while origin, labelling, and paperwork are verified, and the buyer typically carries that administrative burden directly.
This is simply a practical reality of cross-border parcel logistics, not a statement about the legality of the underlying compound. It applies whether the contents are pharmaceuticals, cosmetics, supplements, or research chemicals — customs processes exist independently of what category a product falls into.
REVIVE LAB UAE holds Retatrutide in stock domestically and dispatches from inside the UAE rather than shipping parcels across an international border to each individual buyer. Practically, this means a purchase from REVIVE is a domestic transaction rather than a personal import — the buyer isn't the one filing customs declarations, dealing with international carriers, or absorbing the risk of a parcel being queried at the border. That structural difference is one of the main reasons UAE-based research groups increasingly prefer sourcing locally rather than ordering directly from overseas vendors.
REVIVE's own practices are deliberately narrow in scope. Every Retatrutide vial is labelled research-use-only, no human dosing or therapeutic claims appear on our product pages, and nothing on this site should be read as medical, dietary, or clinical guidance. We do not claim MOHAP drug registration or any pharmaceutical marketing authorisation — REVIVE operates as a supplier of laboratory-grade research material, and it is the buyer's responsibility to use that material appropriately and in line with the rules that apply to their own research context.
| Spec | Detail |
|---|---|
| Form | Lyophilised powder, 10 mg vial |
| Molecular weight | ≈4731 Da |
| Purity (HPLC) | ≥99.0% |
| Class | Triple agonist research peptide (GLP-1 / GIP / GCG pathways) |
| Labelling | Research use only — not for human or veterinary use |
| Price | AED 449 per 10 mg vial |
Research-grade Retatrutide supplied for laboratory and research purposes is generally classified as an unscheduled research chemical rather than a controlled substance or licensed prescription pharmaceutical in the UAE. It is sold strictly as a research reference material. This is general information, not legal advice — confirm specifics with UAE customs, MOHAP, or a qualified lawyer for your situation.
Retatrutide is an investigational compound still under pharmaceutical research globally and is not currently marketed as a licensed prescription product under any brand name in the UAE, nor is research-grade material treated as a narcotic or scheduled drug when correctly labelled for laboratory use.
Buying from a UAE-based supplier already holding domestic stock avoids the customs paperwork, delays, and interception risk that come with personal international shipments — the purchase becomes a domestic transaction rather than a cross-border import.
No. REVIVE operates as a research-chemical supplier and does not claim MOHAP drug registration or any specific regulatory approval beyond HPLC-verified research material with clear non-human-consumption labelling.